This Week’s CGT News: Radiopharmaceutical Boosts CAR T - Takeaways - MDSpire
Advertisement
This Week’s CGT News: Radiopharmaceutical Boosts CAR T
A targeted radiopharmaceutical improves CAR T activity in neuroblastoma models, engineered Tregs suppress allergic asthma, and new gene therapy platforms target MMA and the brain
CAR 422 is a mesothelin-targeting CAR T cell that shows activity in ovarian and pancreatic cancer by targeting a juxtamembrane stump of mesothelin.
2
Engineered regulatory T cells, or CAlleR Tregs, reduced allergic asthma symptoms in mice by suppressing allergen-specific immune responses.
3
A targeted radiopharmaceutical improved CAR T cell therapy in neuroblastoma models, enhancing tumor regression and reshaping the tumor microenvironment.
4
A liver-directed lentiviral gene therapy showed durable effects in mouse models of methylmalonic acidemia, with high gene transfer efficiency.
5
A gene therapy platform using engineered AAV5 capsids targets human glial cells in the brain, addressing challenges in neurological gene therapy.
